Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Amryt Pharma's Lojuxta approved for funding as NHS treatment

David Allmond, chief commercial officer at Amryt Pharma PLC (LON:AMYT) tells Proactive Investors their Lojuxta Homozygous Familial Hypercholesterolaemia (HoFH) treatment is to be made available to NHS patients in England.

HoFH is a rare life-threatening disorder that causes abnormally high levels of low density lipoprotein (LDL) cholesterol.

 
Meet Anglo Asian Mining PLC, Jersey Oil and Gas PLC, Europa Oil & Gas (Holdings) Plc, ANGLE plc and Eurasia Mining plc at our event, Dublin , 22 November 2018. Register here »
View full AMYT profile View Profile

Amryt Pharma PLC Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use